Fig. 3.

Targeting metabolic vulnerabilities reduced breast cancer cell viability. a Extracellular acidification rate (ECAR) in Hs578T cells treated acutely with 0.5 and 4 mM 2-deoxyglucose (2DOG). b Cell viability in Hs578T cells. c MCF10a cells treated with 0.5 and 4 mM 2DOG for 2 days. d Oxygen consumption rate (OCR) in ESH-172 cells treated acutely with 2 and 4 nM oligomycin. e Cell viability in ESH-172 cells treated with 2 and 4 nM oligomycin for 2 and 3 days. f Cell viability in MCF10a cells treated with 2 and 4 nM oligomycin for 3 days. g OCR in ESH-172 cells treated acutely with 1 and 4 mM metformin. h Cell viability in ESH-172 cells treated with 1 and 4 mM metformin for 2 and 3 days. i Cell viability in MCF10a cells treated with 1 and 4 mM metformin for 3 days. All data are mean ± SEM, n = 3–7 biological replicates/group. *p < 0.05 vs. vehicle